IntroductionNeoadjuvant chemoimmunotherapy significantly improves surgical resection rates, major pathological response rates (MPR), pathological complete response rates (pCR), and survival rates in patients with resectable NSCLC. Through systematic re…
BackgroundBullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. Novel biologic agents represent a potential therapeutic option. We explore the use of dupilumab in the treatment of BP.MethodsRelevant studies pub…
BackgroundPeripheral immune tolerance is a key mechanism for maintaining immune homeostasis and preventing autoimmune responses. Although numerous studies have explored its molecular and cellular basis, a comprehensive and systematic overview of the fi…
BackgroundProgressive pulmonary fibrosis (PPF) is a major cause of poor prognosis in connective tissue disease-associated interstitial lung disease (CTD-ILD). This study aims to analyze and evaluate the incidence of PPF and related influencing factors …
BackgroundAlthough the existence of antiphospholipid antibodies (aPL) has been extensively documented as a risk factor for thrombocytopenia, hemolytic anemia, and recurrent miscarriage, their contribution to renal damage in the context of the systemic …
BackgroundImmunotherapy has revolutionized the therapeutic paradigm for lung cancer, yet its clinical efficacy exhibits significant interpatient heterogeneity. The implementation of personalized immunotherapy critically depends on the precise identific…
BackgroundVascularized composite allotransplantation (VCA) offers unique reconstructive solutions for severe tissue loss, restoring form and function. Acute and chronic rejection remains a significant barrier, with acute episodes occurring in most reci…
ObjectiveTo assess platelet-to-lymphocyte ratio (PLR) prognostic utility for overall (OS) and progression-free survival (PFS) in immune checkpoint inhibitor-treated cancer patients, and examine impacts of geography, cancer type, cutoff, ICI class, trea…
IntroductionWe conducted an etiology-stratified network meta-analysis of first-line systemic therapies for advanced HCC to compare newer regimens beyond sorafenib-based RCT evidence (HBV, HCV, or non-viral).MethodsFollowing PRISMA-NMA, we searched PubM…
BackgroundPembrolizumab-induced immune-related oral mucositis (irOM) is a rare and often underrecognized toxicity. This study aimed to systematically characterize its clinical profile, histopathologic patterns, management strategies, and outcomes to su…
